Literature DB >> 9783356

[Surgical pain therapy in inoperable metastatic epigastric tumor by bilateral thoracoscopic splanchnicectomy].

D Inderbitzin1, R A Schmid, O Schöb, W Weder.   

Abstract

Patients with unresectable supramesenteric malignancies often suffer from intractable pain. The supramesenteric viscera are supplied by the greater splanchnic nerve. Surgical options to effectively denervate the supramesenteric area are coeliac ganglionectomy, open or percutaneous coeliac ganglion block or transhiatal bilateral splanchnicotomy. The surgical minimally invasive alternative is thoracoscopic splanchnicectomy. In 7 patients pain was scored on a scale from 1 (no pain) to 10 (maximal pain) before and after surgery and weekly thereafter. Five bilateral and 2 left-sided thoracoscopic splanchnicectomies were performed. Operation time was 17 +/- 3 min for each side. The mean pain score dropped from preoperatively (under morphine sulphate medication) 7.4 +/- 0.6 to 4.9 (2.5-8.25) 1 week postoperatively (p = 0.02) and to 4.9 (2.5-6.75) 7 weeks postoperatively (p = 0.02). The relief from back pain was immediate and complete, but abdominal pain tended to recur. Six of our 7 patients and their general practitioners rated the intervention as a success. Thoracoscopic splanchnicectomy affords excellent palliation in patients with unresectable supramesenteric tumour, offering reliable pain control.

Entities:  

Mesh:

Year:  1998        PMID: 9783356

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  2 in total

1.  Anatomy of the thoracic splanchnic nerves in pigs.

Authors:  O Orhan; A Duzler
Journal:  Vet Res Commun       Date:  2006-12-23       Impact factor: 2.459

2.  Assessment of quality of life in patients with non-operated pancreatic cancer after videothoracoscopic splanchnicectomy.

Authors:  Jacek Smigielski; Lukasz Piskorz; Marcin Wawrzycki; Leszek Kutwin; Piotr Misiak; Marian Brocki
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2011-09-30       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.